Stemtech 3Q 2026: Revenue $282.48K, EPS ($0.00) — 10-Q Summary
Stemtech reported 3Q 2026 revenue of $282.48K, down 67% YoY, citing a smaller distributor base. Net income improved to a loss of $478.58K, as lower expenses offset declining gross profit. The company is working to recruit and re-engage distributors and has restored product supply.
How this was made
The 30-second read
Why it matters
The earnings miss is likely to trigger short‑term selling pressure, but the restored supply and marketing partnership may offer a longer‑term upside.
Market read
Micro‑cap investors will reassess valuation; broader market impact is negligible.
What to watch
The new Tony Little partnership could boost brand awareness and future sales.
Background
Stemtech Corp filed its Q3 2026 10‑Q, highlighting a steep revenue decline and ongoing losses after product shortages earlier in the year.
Ticker impact
Stemtech reported Q3 2026 revenue of $282.48K, a 67% YoY decline, and a net loss of $478.58K in its 10‑Q filing.
likely pressure as the market prices in the revenue decline and loss
Quarterly results are the first public disclosure of these figures and show a material deterioration in top‑line performance.
Market effects
The decline may weigh on other niche health‑tech distributors tracking similar revenue trends.
Limited to U.S. micro‑cap investors; no broader regional effect.
Minimal global impact given the company's small size.
Counterpoint
If the supply restoration leads to a rebound in distributor orders, the stock could recover quickly.
Key entities
- companyStemtech Corp
Micro‑cap health‑tech distributor reporting Q3 2026 results.
